PL1648874T3 - Pochodne piperazyny i ich zastosowanie jako środków leczniczych - Google Patents

Pochodne piperazyny i ich zastosowanie jako środków leczniczych

Info

Publication number
PL1648874T3
PL1648874T3 PL04779562T PL04779562T PL1648874T3 PL 1648874 T3 PL1648874 T3 PL 1648874T3 PL 04779562 T PL04779562 T PL 04779562T PL 04779562 T PL04779562 T PL 04779562T PL 1648874 T3 PL1648874 T3 PL 1648874T3
Authority
PL
Poland
Prior art keywords
therapeutic agents
piperazine derivatives
piperazine
derivatives
therapeutic
Prior art date
Application number
PL04779562T
Other languages
English (en)
Inventor
Melwyn Abreo
Mikhail Chafeev
Nagasree Chakka
Sultan Chowdhury
Jian-Min Fu
Heinz W Gschwend
Mark W Holladay
Duanjie Hou
Rajender Kamboj
Vishnumurthy Kodumuru
Wenbao Li
Shifeng Liu
Vandna Raina
Sengen Sun
Shaoyi Sun
Serguei Sviridov
Chi Tu
Michael D Winther
Zaihui Zhang
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34120234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1648874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PL1648874T3 publication Critical patent/PL1648874T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL04779562T 2003-07-30 2004-07-29 Pochodne piperazyny i ich zastosowanie jako środków leczniczych PL1648874T3 (pl)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US49109503P 2003-07-30 2003-07-30
US54693404P 2004-02-23 2004-02-23
US54678604P 2004-02-23 2004-02-23
US54682004P 2004-02-23 2004-02-23
US54681504P 2004-02-23 2004-02-23
US54689804P 2004-02-23 2004-02-23
US55341604P 2004-03-16 2004-03-16
US55344604P 2004-03-16 2004-03-16
US55340404P 2004-03-16 2004-03-16
US55340304P 2004-03-16 2004-03-16
US55349104P 2004-03-16 2004-03-16
EP04779562A EP1648874B1 (en) 2003-07-30 2004-07-29 Piperazine derivatives and their use as therapeutic agents
PCT/US2004/024548 WO2005011655A2 (en) 2003-07-30 2004-07-29 Pyridazine derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
PL1648874T3 true PL1648874T3 (pl) 2012-04-30

Family

ID=34120234

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04779562T PL1648874T3 (pl) 2003-07-30 2004-07-29 Pochodne piperazyny i ich zastosowanie jako środków leczniczych

Country Status (23)

Country Link
US (1) US7335658B2 (pl)
EP (3) EP2316827B1 (pl)
JP (1) JP4808616B2 (pl)
KR (1) KR100934554B1 (pl)
AR (1) AR047557A1 (pl)
AT (1) ATE527242T1 (pl)
AU (2) AU2004261252C1 (pl)
CA (1) CA2533899C (pl)
CY (1) CY1112178T1 (pl)
DK (1) DK1648874T3 (pl)
EC (1) ECSP066313A (pl)
ES (2) ES2568769T3 (pl)
HK (1) HK1226399A1 (pl)
HR (1) HRP20110974T1 (pl)
IL (1) IL173395A (pl)
MA (1) MA28011A1 (pl)
NO (1) NO332822B1 (pl)
NZ (1) NZ545265A (pl)
PL (1) PL1648874T3 (pl)
PT (1) PT1648874E (pl)
TN (1) TNSN06034A1 (pl)
TW (2) TW201038270A (pl)
WO (1) WO2005011655A2 (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) * 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
SG145699A1 (en) * 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) * 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
RU2006105717A (ru) * 2003-07-30 2007-09-20 Зинон Фармасьютиклз Инк. (Ca) Производные пиперазина и их применение в качестве терапевтических агентов
WO2005072681A2 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
EP1807085B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101090724A (zh) * 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5149009B2 (ja) * 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
WO2006034279A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
WO2006125180A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
WO2007044085A2 (en) * 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007005763A2 (en) * 2005-07-01 2007-01-11 Novartis Ag Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007071023A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2007136746A2 (en) * 2006-05-19 2007-11-29 Xenon Pharmaceuticals Inc. Macrocyclic compounds and their uses as stearoyl-coa desaturase
PT2029572E (pt) 2006-06-05 2011-02-09 Novartis Ag Compostos orgânicos
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
US8246433B2 (en) * 2006-08-25 2012-08-21 Alma Mater Sports, Llc Team based fantasy sport contest
WO2008056687A1 (en) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Novel spiropiperidine derivative
KR20090083477A (ko) * 2006-11-20 2009-08-03 그렌마크 파머수티칼스 에스. 아. 스테아로일-ＣｏＡ 불포화효소 저해제인 아세틸렌 유도체
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2125799A1 (en) * 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
RU2489431C2 (ru) * 2007-04-23 2013-08-10 Янссен Фармацевтика Н.В. Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
RS52518B (sr) * 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
US20090170867A1 (en) * 2007-04-27 2009-07-02 Shionogi & Co., Ltd. Trpv1 antagonists including sulfonamide substituent and uses thereof
AU2008287542C1 (en) 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
MX2010001485A (es) 2007-08-08 2010-06-01 Graceway Pharmaceuticals Llc Derivado de fenoxi-pirrolidina y su uso, y composiciones.
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
KR101198582B1 (ko) * 2007-12-11 2012-11-06 에프. 호프만-라 로슈 아게 스테아로일-ｃｏａ 불포화화 효소의 억제제
LT2307374T (lt) 2008-07-31 2017-04-25 Janssen Pharmaceutica Nv Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai
ES2545864T3 (es) 2009-02-17 2015-09-16 Merck Canada Inc. Nuevos compuestos espiránicos útiles como inhibidores de la estearoil-coenzima A delta-9 desaturasa
EP2459568A4 (en) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd NEW SPIRO COMPOUNDS AS AN INHIBITORS OF STEAROYL COENZYME A DELTA 9 DESATURASE
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2475367A1 (en) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
MX2012004078A (es) 2009-10-09 2012-07-25 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
AU2013241854B2 (en) * 2012-03-28 2017-11-02 Intervet International B.V. Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
RU2014149559A (ru) 2012-05-22 2016-06-27 Ийсум Рисёч Девелопмент Кампани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Селективные ингибиторы недифференцированных клеток
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
JP6905530B2 (ja) 2015-09-16 2021-07-21 メタクリン，インク． ファルネソイドｘ受容体アゴニストとその使用
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
HRP20251322T1 (hr) 2017-03-15 2025-12-05 Eli Lilly And Company Agonisti receptora farnesoid x i njihova upotreba
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
SG11202011083PA (en) * 2018-05-09 2020-12-30 Lg Chemical Ltd Novel compound exhibiting enteropeptidase inhibitory activity
HRP20251321T1 (hr) 2018-09-18 2025-12-05 Eli Lilly And Company Agonisti farnezoid x receptora i njihova primjena
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CA3171987A1 (en) 2020-03-18 2021-09-23 Nicholas D. Smith Crystalline forms of a farnesoid x receptor agonist
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US667452A (en) * 1900-09-08 1901-02-05 John A Hendrickson Computing attachment for pumps.
US2985657A (en) 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
JPH02502824A (ja) 1987-04-03 1990-09-06 ジ・アップジョン・カンパニー アミノ‐９，１０‐セコステロイド類
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5166147A (en) 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity
GB9019143D0 (en) * 1990-09-01 1990-10-17 Bp Chem Int Ltd Thixotropic compositions
EP0520292A1 (de) 1991-06-19 1992-12-30 Hoechst Aktiengesellschaft Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SI0876366T1 (en) 1996-01-15 2001-12-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
DK1064273T3 (da) 1998-03-19 2003-03-31 Upjohn Co 1,3,4-Thiadiazoler, som er nyttige til behandling af CMV-infektioner
AU6227399A (en) 1998-10-21 2000-05-08 Takeda Chemical Industries Ltd. Fused pyridazine derivatives, process for the preparation of the same and uses thereof
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
EP1156045A4 (en) 1999-01-28 2002-04-17 Nippon Shinyaku Co Ltd AMID DERIVATIVES AND DRUG COMPOSITIONS
EP1147112B1 (en) 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
DK1035115T3 (da) 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
AU779550B2 (en) 1999-04-09 2005-01-27 Meiji Seika Kaisha Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
JP3637961B2 (ja) * 1999-09-16 2005-04-13 田辺製薬株式会社 芳香族含窒素六員環化合物
US6677452B1 (en) 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
EP1243268A4 (en) 1999-12-14 2003-05-21 Nippon Shinyaku Co Ltd MEDICINAL COMPOSITION
US6987001B2 (en) 2000-02-24 2006-01-17 Xenon Pharmaceuticals Inc. Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
DE60130771T2 (de) * 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
EP1322767B1 (en) 2000-09-26 2008-07-23 Xenon Pharmaceuticals Inc. Methods and compositions employing a stearoyl-coa desaturase-hscd5
DE10060412A1 (de) 2000-12-05 2002-06-06 Bayer Ag DELTA1-Pyrroline
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
CN1703401A (zh) * 2001-05-22 2005-11-30 神经原公司 黑色素浓集激素受体的配体:取代的1－苄基－4－芳基哌嗪类似物
DE60230266D1 (de) 2001-06-15 2009-01-22 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
WO2003037862A1 (en) 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Amide derivatives and drugs
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
WO2003045921A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
US7449457B2 (en) 2001-12-07 2008-11-11 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
EP1474401A2 (en) 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
MY140390A (en) 2002-03-13 2009-12-31 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
ATE395343T1 (de) 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
CA2493584A1 (en) 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Inhibition of stearoyl-coa desaturase 1 (scd1) increases insulin sensitivity and treats diabetes
AU2003301436A1 (en) 2002-10-17 2004-05-04 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
SG145699A1 (en) 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
RU2006105717A (ru) 2003-07-30 2007-09-20 Зинон Фармасьютиклз Инк. (Ca) Производные пиперазина и их применение в качестве терапевтических агентов

Also Published As

Publication number Publication date
JP4808616B2 (ja) 2011-11-02
CA2533899A1 (en) 2005-02-10
EP2316827B1 (en) 2016-01-27
TWI345974B (en) 2011-08-01
MA28011A1 (fr) 2006-07-03
HK1097256A1 (zh) 2007-06-22
US20050065143A1 (en) 2005-03-24
CA2533899C (en) 2011-01-04
NZ545265A (en) 2009-11-27
AU2004261252B2 (en) 2009-02-05
EP3042895A1 (en) 2016-07-13
ES2375134T3 (es) 2012-02-27
ES2568769T3 (es) 2016-05-04
PT1648874E (pt) 2011-12-23
CY1112178T1 (el) 2015-12-09
TW200518753A (en) 2005-06-16
WO2005011655A3 (en) 2005-03-24
IL173395A (en) 2013-03-24
AU2009201788A1 (en) 2009-05-28
JP2007500717A (ja) 2007-01-18
TW201038270A (en) 2010-11-01
NO20060981L (no) 2006-05-02
US7335658B2 (en) 2008-02-26
KR100934554B1 (ko) 2009-12-29
KR20060036107A (ko) 2006-04-27
EP1648874A2 (en) 2006-04-26
ATE527242T1 (de) 2011-10-15
HRP20110974T1 (hr) 2012-01-31
TNSN06034A1 (en) 2007-10-03
AR047557A1 (es) 2006-01-25
DK1648874T3 (da) 2012-01-23
AU2004261252C1 (en) 2009-09-17
EP1648874B1 (en) 2011-10-05
NO332822B1 (no) 2013-01-21
ECSP066313A (es) 2006-07-28
HK1226399A1 (en) 2017-09-29
WO2005011655A2 (en) 2005-02-10
IL173395A0 (en) 2006-06-11
AU2009201788B2 (en) 2012-04-05
EP2316827A1 (en) 2011-05-04
AU2004261252A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
PL1648874T3 (pl) Pochodne piperazyny i ich zastosowanie jako środków leczniczych
IL173398A0 (en) Pyridyl derivatives and their use as therapeutic agents
SG145701A1 (en) Piperazine derivatives and their use as therapeutic agents
TWI349551B (en) Thiophenepyrimidinone derivatives and their use in therapy
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
GB0303910D0 (en) Therapeutic agents
GB0308318D0 (en) Therapeutic agents
GB0324761D0 (en) Use of compounds in therapy
EP1682136A4 (en) THERAPEUTIC COMPOUNDS AND CORRESPONDING USES THEREOF
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
PL1694649T3 (pl) Pochodne 2-pirydynyloetylokarboksyamidu i ich zastosowanie jako fungicydów
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
GB0314129D0 (en) Therapeutic agents
GB0311201D0 (en) Therapeutic agents
GB0301350D0 (en) Therapeutic agents
GB0207410D0 (en) Compounds and their therapeutic use
GB0314136D0 (en) Therapeutic agents
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
AU2003205963A8 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
AU2003218715A8 (en) Azepane derivatives and their use as atk1 inhibitors
GB0304524D0 (en) Therapeutic agents
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
ZA200704650B (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
GB0324902D0 (en) Therapeutic agents